Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 3 papers. Top paper: “Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial”.
Anthony R Mato, Ahmet Dogan, Venkatraman E Seshan, Erel Joffe, Kelsey Flaherty +41 more
Peter A. Riedell, Stephanie Feldman, Gina George, Stephen Sansoterra, Thomas Althaus +29 more
Chad Vanderbilt, Teng Fei, Ticiane Henriques Santa Rita, A. Rivas Delgado, Annie Qiu +31 more